Browne_1998_Biopharm.Drug.Dispos_19_309

Reference

Title : The influence of plasma butyrylcholinesterase concentration on the in vitro hydrolysis of cocaine in human plasma - Browne_1998_Biopharm.Drug.Dispos_19_309
Author(s) : Browne SP , Slaughter EA , Couch RA , Rudnic EM , McLean AM
Ref : Biopharmaceutics & Drug Disposition , 19 :309 , 1998
Abstract :

In humans, the plasma enzyme butyrylcholinesterase, BChE (EC 3.1.1.8), mediates the in vivo plasma hydrolysis of cocaine to the pharmacologically inactive metabolite ecgonine methyl ester, EME. This enzyme has been purified from human plasma to investigate the potential as a treatment for cocaine intoxication. Cocaine (2.1 micrograms mL-1) was incubated in plasma with a BChE concentration in the normal range (3.02 micrograms mL-1) and in plasma with enhanced BChE concentrations of 9.14, 20.8 and 37.8 micrograms mL-1, respectively for time periods up to 120 min. Cocaine and the hydrolytic products, ecgonine methyl ester and ecgonine, were quantified simultaneously by gas chromatography-mass spectrometry (GC-MS). The enhancement of plasma BChE concentration resulted in a dramatic increase in the rate of hydrolysis of cocaine. There was a stoichimetric conversion of cocaine to the inactive hydrolysis product, ecgonine methyl ester. Accordingly, the half-life of cocaine in plasma decreased significantly with enhanced BChE concentration. At plasma BChE concentrations of 3.02, 9.14, 20.8 and 37.8 micrograms mL-1, half-life values of 116, 35.8, 21.4 and 9.0 min, respectively were observed. The marked reduction in cocaine half-life provides evidence supporting the potential therapeutic use of BChE for the treatment of cocaine intoxication.

PubMedSearch : Browne_1998_Biopharm.Drug.Dispos_19_309
PubMedID: 9673783

Related information

Substrate Cocaine

Citations formats

Browne SP, Slaughter EA, Couch RA, Rudnic EM, McLean AM (1998)
The influence of plasma butyrylcholinesterase concentration on the in vitro hydrolysis of cocaine in human plasma
Biopharmaceutics & Drug Disposition 19 :309

Browne SP, Slaughter EA, Couch RA, Rudnic EM, McLean AM (1998)
Biopharmaceutics & Drug Disposition 19 :309